Payment overview · 2025
General Payments
$1,195.15
69 reported records · 20 companies
Healthcare provider profile · identity verified
Robert T. Wesley, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FRANKLIN, KY · NPI 1144275348
Verified facts
What the public records show
CMS Open Payments records show Robert T. Wesley, M.D. received $1,195.15 in general payments during 2025 across 69 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Otezla, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 510 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $180.72 | 15.1% | 11 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $160.65 | 13.4% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $150.86 | 12.6% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $117.85 | 9.9% | 6 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $82.43 | 6.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $80.97 | 6.8% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $80.14 | 6.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.37 | 4.3% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.77 | 3.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $36.53 | 3.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.21 | 2.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.44 | 2.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.76 | 2.0% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.67 | 1.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.96 | 1.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.61 | 1.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.11 | 1.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.46 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.98 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.66 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,195.15 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $180.72 | 11 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $160.65 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $101.92 | 5 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $82.43 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $82.13 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $80.97 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $80.14 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.37 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.37 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.34 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.16 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $43.87 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.69 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $36.53 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.44 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 80 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 135 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 15 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 170 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
121 | 36 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
170 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
135 | 30 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
510 | 87 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1175 | 285 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1053 | 263 |
| Omeprazole | Omeprazole | 845 | 215 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 732 | 220 |
| Amlodipine Besylate | Amlodipine Besylate | 722 | 191 |
| Losartan Potassium | Losartan Potassium | 688 | 193 |
| Furosemide | Furosemide | 657 | 177 |
| Pantoprazole Sodium | Pantoprazole Sodium | 656 | 175 |
| Metoprolol Tartrate | Metoprolol Tartrate | 553 | 141 |
| Lisinopril | Lisinopril | 544 | 153 |
| Metformin Hcl | Metformin Hcl | 530 | 138 |
| Eliquis | Apixaban | 510 | 87 |
| Gabapentin | Gabapentin | 467 | 116 |
| Metoprolol Succinate | Metoprolol Succinate | 444 | 116 |
| Quetiapine Fumarate | Quetiapine Fumarate | 415 | 103 |
| Donepezil Hcl | Donepezil Hcl | 410 | 90 |
| Sertraline Hcl | Sertraline Hcl | 386 | 89 |
| Prednisone | Prednisone | 383 | 258 |
| Glimepiride | Glimepiride | 352 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 325 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 294 | 89 |
| Buspirone Hcl | Buspirone Hcl | 276 | 80 |
| Trazodone Hcl | Trazodone Hcl | 272 | 80 |
| Montelukast Sodium | Montelukast Sodium | 271 | 64 |
| Meloxicam | Meloxicam | 266 | 72 |
| Potassium Chloride | Potassium Chloride | 265 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 262 | 76 |
| Escitalopram Oxalate | Escitalopram Oxalate | 258 | 67 |
| Carvedilol | Carvedilol | 256 | 66 |
| Famotidine | Famotidine | 254 | 65 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 250 | 68 |
| Allopurinol | Allopurinol | 248 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 244 | 73 |
| Amitriptyline Hcl | Amitriptyline Hcl | 234 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 224 | 58 |
| Spironolactone | Spironolactone | 192 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 74 |
| Warfarin Sodium | Warfarin Sodium | 185 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 184 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 172 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 170 | 35 |
| Mirtazapine | Mirtazapine | 167 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 160 | 56 |
| Simvastatin | Simvastatin | 148 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 140 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 139 | 38 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 139 | 95 |
| Clonidine Hcl | Clonidine Hcl | 135 | 41 |
| Ozempic | Semaglutide | 135 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 134 | 27 |
| Atenolol | Atenolol | 130 | 35 |
| Ezetimibe | Ezetimibe | 129 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 125 | 37 |
| Finasteride | Finasteride | 121 | 36 |
| Synthroid | Levothyroxine Sodium | 121 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 119 | 34 |
| Sucralfate | Sucralfate | 119 | 44 |
| Paroxetine Hcl | Paroxetine Hcl | 118 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 117 | 31 |
| Clonazepam | Clonazepam | 115 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 108 | 82 |
| Metoclopramide Hcl | Metoclopramide Hcl | 108 | 20 |
| Temazepam | Temazepam | 107 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 106 | 28 |
| Alendronate Sodium | Alendronate Sodium | 105 | 28 |
| Celecoxib | Celecoxib | 103 | 24 |
| Tramadol Hcl | Tramadol Hcl | 103 | 37 |
| Memantine Hcl | Memantine Hcl | 97 | 22 |
| Methocarbamol | Methocarbamol | 96 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | 23 |
| Baclofen | Baclofen | 90 | 13 |
| Repatha Sureclick | Evolocumab | 90 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 56 |
| Glipizide | Glipizide | 87 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 86 | 22 |
| Risperidone | Risperidone | 85 | 14 |
| Azithromycin | Azithromycin | 82 | 59 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 24 |
| Levetiracetam | Levetiracetam | 81 | 17 |
| Jardiance | Empagliflozin | 80 | suppressed |
| Alprazolam | Alprazolam | 79 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 79 | 28 |
| Ondansetron Odt | Ondansetron | 79 | 40 |
| Topiramate | Topiramate | 79 | 16 |
| Clindamycin Hcl | Clindamycin Hcl | 77 | 58 |
| Nifedipine Er | Nifedipine | 77 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 75 | 18 |
| Meclizine Hcl | Meclizine Hcl | 75 | 25 |
| Xarelto | Rivaroxaban | 74 | 17 |
| Levofloxacin | Levofloxacin | 73 | 58 |
| Testosterone Cypionate | Testosterone Cypionate | 71 | 18 |
| Divalproex Sodium | Divalproex Sodium | 70 | 16 |
| Lorazepam | Lorazepam | 70 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 68 | 39 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 67 | 22 |
| Estradiol | Estradiol | 66 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 61 | suppressed |
| Trulicity | Dulaglutide | 60 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 12 |
| Doxepin Hcl | Doxepin Hcl | 58 | 11 |
| Nystatin | Nystatin | 58 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 12 |
| Farxiga | Dapagliflozin Propanediol | 56 | 16 |
| Metformin Hcl Er | Metformin Hcl | 56 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 56 | 13 |
| Cefdinir | Cefdinir | 54 | 47 |
| Clarithromycin | Clarithromycin | 54 | 49 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 12 |
| Megestrol Acetate | Megestrol Acetate | 54 | 27 |
| Propranolol Hcl | Propranolol Hcl | 54 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 21 |
| Chlorthalidone | Chlorthalidone | 48 | 15 |
| Mupirocin | Mupirocin | 48 | 26 |
| Ibuprofen | Ibuprofen | 47 | 22 |
| Haloperidol | Haloperidol | 46 | suppressed |
| Valsartan | Valsartan | 46 | 12 |
| Bumetanide | Bumetanide | 45 | suppressed |
| Lidocaine | Lidocaine | 45 | suppressed |
| Linzess | Linaclotide | 45 | 12 |
| Diazepam | Diazepam | 44 | 23 |
| Gentamicin Sulfate | Gentamicin Sulfate | 44 | 23 |
| Lovastatin | Lovastatin | 44 | 13 |
| Promethazine Hcl | Promethazine Hcl | 43 | 16 |
| Midodrine Hcl | Midodrine Hcl | 41 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 40 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | suppressed |
| Digoxin | Digoxin | 39 | suppressed |
| Lansoprazole | Lansoprazole | 37 | 12 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 36 | suppressed |
| Colchicine | Colchicine | 36 | 13 |
| Telmisartan | Telmisartan | 36 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 36 | 11 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 11 |
| Dutasteride | Dutasteride | 34 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 11 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | 22 |
| Fluconazole | Fluconazole | 33 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 22 |
| Azelastine Hcl | Azelastine Hcl | 31 | 14 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Clonidine | Clonidine | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 29 |
| Nitroglycerin | Nitroglycerin | 30 | 22 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 30 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 30 | 13 |
| Lactulose | Lactulose | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Loperamide | Loperamide Hcl | 28 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Metronidazole | Metronidazole | 26 | 23 |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Glucagon Emergency Kit | Glucagon | 25 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | 14 |
| Metolazone | Metolazone | 21 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 18 | 11 |
| Glycopyrrolate | Glycopyrrolate | 18 | suppressed |
| Indomethacin | Indomethacin | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ssd | Silver Sulfadiazine | 18 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 15 |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Roflumilast | Roflumilast | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Otezla | Apremilast | 13 | suppressed |
| Procrit | Epoetin Alfa | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Lamotrigine Odt | Lamotrigine | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Adderall | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fluorouracil | Fluorouracil | 11 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,195.15 · 69 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, GEMTESA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, NEXLETOL, OTEZLA, Ozempic, PAXLOVID, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error